Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Status:
Not yet recruiting
Trial end date:
2025-01-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the
efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after
48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary
sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without
immunosuppressant therapy.